Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2006

View Archived Issues

PowderMed's vaccine approach achieves crossprotection for influenza and drifting strains

Nuvo Research acquires fqubed

IDM Pharma completes sale of non-core assets to Pharmexa

Closing of Pain Therapeutics and King's strategic alliance

pSivida completes acquisition of Control Delivery Systems

MAA completed for Genasense plus chemotherapy in malignant melanoma

InterMune completes sale of Infergen to Valeant

Amarin licenses LAX-202 rights for MS fatigue to Multicell Technologies

Anturol completes phase II dose-ranging study

U.S. Navy to receive defense appropriation for Hemopure R&D

Inex shareholders to vote on Targeted Immunotherapy spin-out

FDA clears NT-proBNP test for new risk stratification use

New quinolone antibacterials emerge from Pfizer R&D

sanofi-aventis prepares and tests new histamine H3 receptor antagonists

Preclinical and clinical erythropoietic activity of CNTO-528

Method for diagnosis/prognosis of wound infection claimed in Ethicon patent

Albaconazole superior to fluconazole in phase II vulvovaginal candidiasis trial

New data support Factor Xa inhibition for thromboprophylaxis

Tamoxifen efficacy in breast cancer affected by CYP450 2D6 genotype

Novel HIV integrase inhibitors designed by Bioflexis

Immunosuppressive effects of NK-026680 useful for acute GVHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...